Transplantation provides superior survival high risk myeloid malignancies in older patients.

Transplant Referral Patterns for Patients (Pts) with Newly Diagnosed (ND) Higher-Risk (HR) Myelodysplastic Syndromes (MDS), and European Leukemianet (ELN) 2010 Intermediate-Risk (IR) or Adverse-Risk (AR) Acute Myeloid Leukemia (AML) in the Connect® MDS/AML Registry Transplant Cell Ther. Disease-free survival in patients with MDS (A, reported by Nakamura et al. [[3]]) and patients with AML (B, reported by Ustun et al. [[5]]) is superior after allogeneic hematopoietic cell transplantation compared with no transplantation. In older patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS), reluctance to refer patients for consideration of allogeneic hematopoietic stem cell transplantation (alloHCT) still remains in some spheres. [Extracted from the article]